Cohance Lifesciences Limited
₹444.45-₹36.90 (-7.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹17,161 Cr
- P/E
- 46.3x
- EV / EBITDA
- 37.0x
- Revenue
- ₹1,094 Cr
- Net margin
- 28.2%
- ROCE
- 19.4%
Price chart
Technical chartScreen technicals →-42.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +0.1%
- 3M
- +4.4%
- 6M
- -8.0%
- 1Y
- -42.9%
- 5Y
- -13.8%
52-week range
Day change -₹36.90 (-7.7%) from ₹481 to ₹444 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in COHANCE, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Operating margin of 38.6% exceeds Healthcare median (24.8%)
Concerns1
- Operating margin declining for 3 consecutive years (44.0% → 39.0% → 33.0%)
Rule-based from financial data. Not advice.
About the company
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.
Read moreShow less
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
- Sector
- Healthcare
- Shares outstanding
- 38.3 Cr shares
- ISIN
- INE03QK01018
- BSE code
- 543064
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹17,161 Cr
- P/E
- 46.3x
- P/B
- 3.9x
- EV / EBITDA
- 37.0x
- EV / Sales
- 16.3x
- P/S
- 16.3x
- Earnings yield
- 2.2%
- 52-week high
- ₹899.70
- 52-week low
- ₹279.75
Profitability
- Operating margin
- 38.6%
- Net margin
- 28.2%
- EBITDA margin
- 44.1%
- ROE
- 14.6%
- ROCE
- 19.4%
- ROA
- 13.4%
- Dividend payout
- 0.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 14.3%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,094 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.7%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹463 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -27.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -8.1%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 1.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹376 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -23.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.1%
Solvency and efficiency
- Current ratio
- 11.29
- Debt / Equity
- 0.03
- Debt / Assets
- 0.03
- Debt / EBITDA
- 0.14
- Interest coverage
- 58.00
- Financial leverage
- 1.09
- CFO / Net profit
- 1.27
- Cash / Market cap
- 2.8%
- Cash per share
- ₹12.35
- Asset turnover
- 0.47
- Fixed asset turnover
- 1.57
- Capital intensity
- 0.64
- Debtor days
- 46 days
- Inventory turnover
- 1.36
- Cash conversion cycle
- 265 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹25 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹731 Cr |
| Sales | Operating profit | ₹363 Cr |
| Operating profit | Interest | ₹8 Cr |
| Operating profit | Depreciation | ₹57 Cr |
| Operating profit | Profit before tax | ₹298 Cr |
| Other income | Profit before tax | ₹54 Cr |
| Profit before tax | Tax and other | ₹79 Cr |
| Profit before tax | Net profit | ₹272 Cr |
Revenue and net profit
Revenue grew 4.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,010 Cr | ₹309 Cr |
| FY2022 | ₹1,320 Cr | ₹558 Cr |
| FY2023 | ₹1,330 Cr | ₹433 Cr |
| FY2024 | ₹1,051 Cr | ₹296 Cr |
| FY2025 | ₹1,094 Cr | ₹272 Cr |
Cash flows
FY2025: ₹301 Cr from operations, -₹20.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹330 Cr | ₹72 Cr |
| FY2022 | ₹270 Cr | ₹180 Cr |
| FY2023 | ₹493 Cr | ₹256 Cr |
| FY2024 | ₹376 Cr | ₹14 Cr |
| FY2025 | ₹301 Cr | -₹20 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,094 Cr+4.1%1Y
- Net profit
- ₹272 Cr-8.1%1Y
- Cash from operations
- ₹301 Cr
- Free cash flow
- -₹20 Cr-242.9%1Y
- Revenue CAGR, 5Y
- 4.7%
- EBITDA CAGR, 5Y
- 2.8%
- Net profit CAGR, 5Y
- 1.9%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,094 Cr | ₹363 Cr | — | ₹272 Cr | ₹301 Cr | -₹20 Cr | 11.7% | +4.1% | -8.1% |
Monthly returns
Month-by-month returns of COHANCE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,588 Cr |
| Equity capital | ₹25 Cr |
| Reserves | ₹2,290 Cr |
| Borrowings | ₹99 Cr |
| Other liabilities | ₹174 Cr |
| Assets | ₹2,588 Cr |
| Fixed assets | ₹685 Cr |
| Capital work in progress | ₹254 Cr |
| Investments | ₹1,116 Cr |
| Other assets | ₹533 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
COHANCE trades at 46.3x earnings against a peer median of 52.6x (a 12% discount).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Cohance Lifesciences LimitedCOHANCEthis companyP/E ↓ discount | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| Sai Life Sciences LimitedSAILIFE | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| Neuland Laboratories Limited.NEULANDLAB | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Dr. Agarwal's Health Care LimitedAGARWALEYE | ₹15,850 Cr | 302.0x | 8.1x | 2.0% | 62.8x |
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTD | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
COHANCE since 1 January, against earlier years.
Historical volatility
COHANCE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 44.0% |
| FY2022 | 44.0% |
| FY2023 | 44.0% |
| FY2024 | 39.0% |
| FY2025 | 33.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,094 Cr |
| Costs | |
| Interest | ₹8 Cr |
| Expenses | ₹731 Cr |
| Operating profitOperating Profit | ₹363 Cr |
| Other income and charges | |
| Profit before tax | ₹351 Cr |
| Tax | |
| Net profitNet Profit | ₹272 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,588 Cr |
| Equity capitalEquity Capital | ₹25 Cr |
| Reserves | ₹2,290 Cr |
| Borrowings | ₹99 Cr |
| Other liabilitiesOther Liabilities | ₹174 Cr |
| AssetsTotal Assets | ₹2,588 Cr |
| Fixed assetsFixed Assets | ₹685 Cr |
| Capital work in progressCWIP | ₹254 Cr |
| Investments | ₹1,116 Cr |
| Other assetsOther Assets | ₹533 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹301 Cr |
| Investing cash flowCash from Investing Activity | -₹321 Cr |
| Financing cash flowCash from Financing Activity | ₹21 Cr |
| Change in cashNet Cash Flow | ₹1 Cr |
Learn while you research
Academy chapters picked for Cohance Lifesciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 46.3, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read